Search

1 to 10 of 430
Sort by

Library Entry
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy

Assessment of the immune status of muscle-invasive bladder cancer (MIBC) has previously shown to be prognostically relevant after treatment with curative intent. The authors conducted this study to develop a clinically applicable immune gene expression assay to predict prognosis and adjuvant...


Library Entry
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

New and fully validated tests need to be brought into clinical practice to improve the estimation of recurrence risk in patients with colon cancer. The aim of this study was to assess the analytical performances of the Immunoscore (IS) and show its contribution to prognosis prediction. The...


Library Entry
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging technologies that can be used to help quantify immune cell subsets,...


Library Entry
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown. The authors state...


Library Entry
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. The authors have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating...


Library Entry
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohor

The biological underpinnings of the prognostic and predictive significance of a relative neutrophilia in patients with non-small lung cancer (NSCLC) are undefined. The authors sought to comprehensively examine the relationships between circulating and intratumoral neutrophil populations and...


Library Entry
Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer

The early response to treatment with immune-checkpoint inhibitors is difficult to evaluate. The authors determined whether changes in integrated [ 18 F]-fluoro-2-deoxy-D-glucose positron emission tomography/MRI ( 18 F-FDG PET/MRI) parameters after the first 2 weeks of antiprogrammed death-1...


Library Entry
Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma

The tumor immune microenvironment has clinicopathological significance in predicting prognosis and therapeutic efficacy. The authors aimed to develop an immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma (NPC). They conclude that the immune signature...


Library Entry
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma

High C reactive protein (CRP) levels have been reported to be associated with a poor clinical outcome in a number of malignancies and with programmed cell death protein 1 immune checkpoint blockade in patients with advanced cancer. Little is known about the direct effects of CRP on adaptive...


Library Entry
Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway have clinical activity in hepatocellular carcinoma (HCC), but only a subset of patients respond to these therapies, highlighting a need for novel biomarkers to...